DelveInsight’s “Acute Ocular Pain Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Acute Ocular Pain, historical and forecasted epidemiology as well as the Acute Ocular Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 

Key Takeaways from the Acute Ocular Pain Market Research Report

• The increase in Acute Ocular Pain market size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Acute Ocular Pain market is anticipated to witness growth at a considerable CAGR.
• The leading Acute Ocular Pain Companies working in the market include Formosa Pharmaceuticals, Surface Ophthalmics, Sun Pharma Advanced Research Company Ltd (SPARC), Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, and others.
• Promising Acute Ocular Pain Pipeline Therapies in the various stages of development include APP13007, SURF-201, SDN-037, DEXTENZA (dexamethasone ophthalmic insert), INVELTYS (loteprednol etabonate ophthalmic suspension/KPI-121), BROMSITE (bromfenac ophthalmic solution), LOTEMAX SM (loteprednol etabonate ophthalmic gel), PROLENSA (bromfenac ophthalmic solution) 0.07%, and others.
• In the 7MM, approximately 15 million people are affected by Acute Ocular Pain (AOP). During the study period, it has been observed that patients with conjunctivitis are the most affected by acute ocular pain.
• In 2022, the United States alone recorded approximately 7 million cases of acute ocular pain (AOP), indicating a substantial burden of this condition within the country. The United States experienced the highest number of AOP cases among all observed regions. Furthermore, projections suggest that the total number of AOP cases is anticipated to increase at a significantly CAGR.
• According to DelveInsight, Acute Ocular Pain affects males and female equally.

 

Discover which therapies are expected to grab the Acute Ocular Pain Market Share @ Acute Ocular Pain Market Outlook

 

Acute Ocular Pain Overview

Acute Ocular Pain (AOP) can arise from a multitude of factors, including trauma, infections, inflammations, or underlying systemic conditions. Understanding the diverse etiologies is crucial for accurate diagnosis and tailored treatment. Eye pain or ocular pain can be differentiated into chronic ocular pain and acute ocular pain. A problem in the eye can cause a feeling of discomfort or pain in the eye. It can also be caused by a problem involving any of the structures around the eye or referred pain from tissues with similar innervation as ocular tissues.

 

Acute Ocular Pain Epidemiology Insights

The epidemiology section of Acute Ocular Pain offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

• Number of Cases of Several Eye Disorders
• Number of Cases of Acute Ocular Pain in Major Eye Disorders

 

Download the report to understand which factors are driving Acute Ocular Pain Epidemiology trends @ Acute Ocular Pain Epidemiological Insights

 

Acute Ocular Pain Therapeutics Market

Therapeutic options for managing AOP include nonpharmacological treatment, such as bandage contact lenses, topical ocular cycloplegic agents, topical ocular nonsteroidal anti-inflammatory agents (NSAIDs), and oral pharmaceutical agents. For treating patients with acute pain, there are generally two categories of oral medications: nonopioid medications and opioid medications. Nonopioid oral medications include prescription or OTC NSAIDs and acetaminophen. Pain associated with surgery, injury, infection, or inflammation at the front of the eye is typically treated with a topical steroid, topical NSAID, systemic NSAID, lubricant ointment, gel or drops, bandage contact lens, or a few doses of oral opiate or topical anesthetic.

 

Acute Ocular Pain Market Insights

Acute Ocular Pain therapies represents an area of significant unmet need. Understanding the AOP microenvironment is critical relative to improving the efficiency of current therapies and the development of more effective approaches. Most of the available treatments in the market target the underlying disease, for example, uveitis, dry eye disease, etc.; hence no approved therapy specifically AOP for exists. Topical and systemic therapies against receptors triggering and processing pain sensations are needed. Readily established systemically applied pain therapies are need to be tested for efficacy in ocular pain. So more companies should be involved in developing the pipeline for targeting the acute ocular patient pool.

 

To know more about Acute Ocular Pain treatment guidelines, visit @ Acute Ocular Pain Treatment Market Landscape

 

Acute Ocular Pain Market Landscape

The landscape for treating acute ocular pain currently faces a scarcity of viable pipeline candidates, with many late-stage therapies from previous years no longer active for this indication. However, there is renewed interest and activity in this area, with emerging players such as SiteOne Therapeutics, Serentrix, Sun Pharma Advanced Research Company Ltd (SPARC)/Visiox, and others developing therapies in the early or preclinical phases.

 

Acute Ocular Pain Drugs Uptake

• SiteOne Therapeutics‘ drug candidate, ST-2578, is currently undergoing Investigational New Drug (IND)-enabling studies for the treatment of ocular surface discomfort. The small molecule drug, currently in development, acts as a Nav1.7 blocker, targeting the Sodium channel protein type IX alpha subunit. This mechanism of action suggests its potential to alleviate eye pain by modulating the activity of Nav1.7 channels involved in sensory transmission.
• Ser-114, a TRPV1 antagonist initially developed by Serentrix LLC, is currently in the preclinical stage of research and development. As a vanilloid receptor antagonist, it holds promise for addressing various conditions such as dry eye syndromes, inflammation, and pain. By targeting the TRPV1 receptor, Ser-114 aims to modulate sensory responses implicated in ocular discomfort and inflammation.
• SDN-037, is a twice-daily topical difluprednate for post-surgical inflammation and pain. Each product utilizes a unique, proprietary, extended-release technology i.e. TJM micellar platform that is patent protected through at least 2036.

 

Major Acute Ocular Pain Companies

Several Acute Ocular Pain companies working in the market include Formosa Pharmaceuticals, Surface Ophthalmics, Sun Pharma Advanced Research Company Ltd (SPARC), Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, and others.

 

Learn more about the FDA-approved drugs for Acute Ocular Pain @ Drugs for Acute Ocular Pain Treatment

 

Scope of the Acute Ocular Pain Market Research Report

• Coverage- 7MM
• Acute Ocular Pain Companies- Formosa Pharmaceuticals, Surface Ophthalmics, Sun Pharma Advanced Research Company Ltd (SPARC), Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, and others.
• Acute Ocular Pain Pipeline Therapies- APP13007, SURF-201, SDN-037, DEXTENZA (dexamethasone ophthalmic insert), INVELTYS (loteprednol etabonate ophthalmic suspension/KPI-121), BROMSITE (bromfenac ophthalmic solution), LOTEMAX SM (loteprednol etabonate ophthalmic gel), PROLENSA (bromfenac ophthalmic solution) 0.07%, and others.
• Acute Ocular Pain Market Dynamics: Acute Ocular Pain Market Drivers and Barriers
• Acute Ocular Pain Market Access and Reimbursement, Unmet Needs, and Future Perspectives

 

Discover more about Acute Ocular Pain Drugs in development @ Acute Ocular Pain Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Executive Summary of Acute Ocular Pain

3. Competitive Intelligence Analysis for Acute Ocular Pain

4. Acute Ocular Pain: Market Overview at a Glance

5. Acute Ocular Pain: Disease Background and Overview

6. Patient Journey

7. Acute Ocular Pain Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Ocular Pain Unmet Needs

10. Key Endpoints of Acute Ocular Pain Treatment

11. Acute Ocular Pain Marketed Products

12. Acute Ocular Pain Emerging Therapies

13. Acute Ocular Pain: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Acute Ocular Pain

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/